Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic H...( Albuferon 1200-mcg Every Two Weeks (A...),Health

Albuferon 1200-mcg Every Two Weeks (Albuferon 1200 Q2w)

-- ITT analysis shows that 55.5% of patients in the Albuferon 1200 Q2w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

67.9% of those in the Albuferon 1200 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q2w

treatment group, 70.6% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- ITT analysis shows that the Albuferon 1200 Q2w treatment group

exhibited a robust early antiviral response (reduction in hepatitis C

RNA viral load to below the level of quantitation): 74.5% for

Albuferon 1200 Q2w at Week 12, vs. 65.8% for peginterferon alfa-2a.

The Albuferon 1200 Q2w treatment group also had the most rapid time to

HCV RNA negativity.

-- The rate of discontinuations due to adverse events was 18.2% in the

Albuferon 1200 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. Dose reductions were attempted in only 24.4% of

Albuferon subjects prior to discontinuation, versus 42.9% for

peginterferon alfa-2a. Adverse events observed were those typically

expected with interferon therapy.

"In the Albuferon Phase 3 trials, we are strongly encouraging titration of dose where necessary to increase tolerability, reduce the rate of discontinuations, and maximize the therapeutic benefit of the robust early antiviral response offered by the 1200-microgram dose on a two-week administration schedule," said Dr. Stump.

Albuferon 1200-mcg Monthly (Albuferon 1200 Q4w)

-- ITT analysis shows that 50.9% of patients in the Albuferon
'/>"/>